Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Journal of Cardiovascular Pharmacology|March 1, 1989
Novel adrenergic compounds. I. Receptor interactions of ABBOTT-54741 [(5,6-dihydroxy-1,2,3,4-tetrahydro-1-naphthtyl)imidazoline], an alpha-adrenergic agonistJ J Kyncl, J F DeBernardis, E N Bush, et al.
European Journal of Epidemiology|June 24, 2005
A study of excess mortality during influenza epidemics in the Czech Republic, 1982-2000J Kyncl, B Prochazka, N L Goddard, et al.
The Journal of Pharmacy and Pharmacology|September 1, 1987
A new nasal decongestant, A-57219: a comparison with oxymetazolineJ F DeBernardis, M Winn, D J Kerkman, et al.
Journal of Medicinal Chemistry|June 1, 1987
Conformationally defined adrenergic agents. 5. Resolution, absolute configuration, and pharmacological characterization of the enantiomers of 2-(5,6-dihydroxy-1,2,3,4-tetrahydro-1-naphthyl)imidazoline: a potent agonist at alpha-adrenoceptorsJ F DeBernardis, D J Kerkman, D L Arendsen, et al.
Journal of Cardiovascular Pharmacology|November 1, 1985
Adrenergic and dopaminergic properties of dopamine sulfoconjugatesJ J Kyncl, S A Buckner, H Brondyk, et al.
Journal of Medicinal Chemistry|April 1, 1986
Conformationally defined adrenergic agents. 2. Catechol imidazoline derivatives: biological effects at alpha 1 and alpha 2 adrenergic receptorsJ F DeBernardis, J J Kyncl, F Z Basha, et al.
Journal of Medicinal Chemistry|April 1, 1976
Drugs derived from cannabinoids. 2. Basic esters of nitrogen and carbocyclic analogsR K Razdan, B Z Terris, H G Pars, et al.
Journal of Medicinal Chemistry|October 1, 1985
Conformationally defined adrenergic agents. 1. Design and synthesis of novel alpha 2 selective adrenergic agents: electrostatic repulsion based conformational prototypesJ F DeBernardis, D J Kerkman, M Winn, et al.
Journal of Medicinal Chemistry|April 1, 1976
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chainsM Winn, D Arendsen, P Dodge, et al.
Alzheimer Disease and Associated Disorders|January 1, 1995
Potential treatment of Alzheimer disease using cholinergic channel activators (ChCAs) with cognitive enhancement, anxiolytic-like, and cytoprotective propertiesS P Arneric, J P Sullivan, M W Decker, et al.
Pageof 4